Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

This is a phase I, open-label study to assess the safety and preliminary efficacy of Fulvestrant in combination with 177Lu-DOTATATE for advanced pNETs.

Trial Details

NCT ID

NCT06663072

Phase

PHASE1

Sponsor

University of Chicago

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

Fulvestrant
177Lu-DOTATATE

Locations (sample)

Chicago, Illinois, United States|41.85003,-87.65005

Key Eligibility Criteria

Patients must have histologically confirmed pancreatic neuroendocrine tumor, WHO grades 1-2, Ki-67 index of \<20%.
Patients must have locally advanced disease that is ineligible for curative-intent resection, or metastatic disease.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter t…
Patients must also have tumors expressing somatostatin receptor, defined as radiotracer avid lesions as assessed by a previous DOTATATE PET scan.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →